At least three published clinical trial protocol amendments for ongoing psilocybin or MDMA trials will cite SSRI/fluoxetine interaction data as justification for modified washout criteria by Q3 2026.

Ongoing psilocybin and MDMA clinical trials will publicly announce changes to their rules about how long people must stop taking SSRIs (common antidepressants like Prozac) before entering the trial. They'll do this because new research shows these drugs interact with psychedelics in ways that matter for safety.

Preclinical fluoxetine-psychedelic interaction data has clear mechanistic relevance to ongoing trials. IRBs and sponsors monitoring the literature are obligated to assess protocol adequacy. However, the path from mouse data to published protocol amendments requires IRB review, sponsor approval, ClinicalTrials.gov update, and in many cases a published amendment notice—all within roughly 5 months of today. That timeline is tight. Three published amendments is a specific, falsifiable bar.